Loading
Life sciences · Journal article
Advanced Healthcare Materials · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The tumor microenvironment (TME) is a complex and heterogeneous milieu encompassing biological and biochemical events and diverse physical, chemical, and mechanical interactions between tumor and stromal cells. This heterogeneity plays a pivotal role in regulating tumor progression, metastasis, and resistance to therapy. In breast cancer, cancer-associated fibroblasts, adipocytes, endothelial cells, and immune cells all contribute to this intricate environment, necessitating precise spatial and cellular modeling to better replicate physiological conditions. Moreover, angiogenesis and metastasis are key contributors to breast cancer mortality. Therefore, three-dimensional (3D) models that incorporate co-cultures of cancer and stromal cells are essential for recreating realistic TMEs. This review highlights the advances in 3D bioprinting technologies for modeling the breast cancer TME. We discuss their potential in drug screening, explore their advantages and limitations, and outline future directions to enhance their fidelity and translational relevance.